Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. May 15, 2023; 15(5): 859-877
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.859
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.859
Table 5 Basic characteristics of followed-up patients with hepatocellular carcinoma (n = 1128), n (%)
| Variables | CNLC staging | |||||||
| Total | Ia | Ιb | IIa | IIb | IIIa | IIIb | IV | |
| Sex | ||||||||
| Male | 922 (81.74) | 261 (80.56) | 152 (79.58) | 21 (75.00) | 252 (84.00) | 151 (84.36) | 60 (78.95) | 25 (83.33) |
| Female | 206 (18.26) | 63 (19.44) | 39 (20.42) | 7 (25.00) | 48 (16.00) | 28 (15.64) | 16 (21.05) | 5 (16.67) |
| Age | ||||||||
| ≤ 50 | 330 (29.26) | 105 (32.41) | 51 (26.70) | 8 (28.57) | 74 (24.67) | 54 (30.17) | 23 (30.26) | 15 (50.00) |
| > 50 | 798 (70.74) | 219 (67.59) | 140 (73.30) | 20 (71.43) | 226 (75.33) | 125 (69.83) | 53 (69.74) | 15 (50.00) |
| Chronic hepatitis | ||||||||
| HBV | 992 (87.94) | 284 (87.65) | 167 (87.43) | 21 (75.00) | 266 (88.67) | 161 (89.94) | 68 (89.47) | 25 (83.33) |
| HCV | 56 (4.96) | 21 (6.48) | 8 (4.19) | 3 (10.71) | 12 (4.00) | 8 (4.47) | 2 (2.63) | 2 (6.67) |
| NAFLD | 62 (5.50) | 14 (4.32) | 14 (7.33) | 3 (10.71) | 17 (5.67) | 6 (3.35) | 6 (7.89) | 2 (6.67) |
| ALD | 18 (1.60) | 5 (1.54) | 2 (1.05) | 1 (3.57) | 5 (1.67) | 4 (2.23) | 0 (0.00) | 1 (3.33) |
| Complications | ||||||||
| Hypertension | 226 (20.04) | 70 (21.60) | 38 (19.90) | 5 (17.86) | 65 (21.67) | 28 (15.64) | 17 (22.37) | 3 (10.00) |
| Diabetes | 159 (14.10) | 2 (12.96) | 21 (10.99) | 6 (21.43) | 49 (16.33) | 24 (13.41) | 11 (14.47) | 6 (20.00) |
| Coronary heart disease | 33 (2.93) | 7 (2.16) | 8 (4.19) | 1 (3.57) | 10 (3.33) | 2 (1.12) | 4 (5.26) | 1 (3.33) |
| Smoking | 408 (36.17) | 121 (37.35) | 68 (35.60) | 8 (28.57) | 101 (33.67) | 67 (37.43) | 30 (39.47) | 13 (43.33) |
| Drinking | 337 (29.88) | 98 (30.25) | 53 (27.75) | 7 (25.00) | 88 (29.33) | 50 (27.93) | 29 (38.16) | 12 (40.00) |
| AFP (ng/mL) | ||||||||
| ≤ 20 | 491 (43.53) | 184 (56.79) | 90 (47.12) | 11 (39.29) | 129 (43.00) | 46 (25.70) | 24 (31.58) | 7 (23.33) |
| 20–400 | 289 (25.62) | 92 (28.40) | 43 (22.51) | 8 (28.57) | 75 (25.00) | 47 (26.26) | 16 (21.05) | 8 (26.67) |
| > 400 | 348 (30.85) | 48 (14.81) | 58 (30.37) | 9 (32.14) | 96 (32.00) | 86 (48.04) | 36 (47.37) | 15 (50.00) |
| Child–Pugh grade | ||||||||
| A | 870 (77.13) | 284 (87.65) | 168 (87.96) | 23 (82.14) | 213 (71.00) | 132 (73.74) | 50 (65.79) | 0 (0.00) |
| B | 228 (20.21) | 40 (12.35) | 23 (12.04) | 5 (17.86) | 87 (29.00) | 47 (26.26) | 26 (34.21) | 0 (0.00) |
| C | 30 (2.66) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 30 (100.00) |
- Citation: Yan YW, Liu XK, Zhang SX, Tian QF. Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China. World J Gastrointest Oncol 2023; 15(5): 859-877
- URL: https://www.wjgnet.com/1948-5204/full/v15/i5/859.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i5.859